StockNews.com Commences Analysis on TherapeuticsMD (NASDAQ:TXMD)

Stock Analysis Introduction

StockNews.com has recently started covering TherapeuticsMD TXMD, a United States-based women's healthcare company, assigning it a "hold" rating. This coverage initiation is likely to attract the attention of investors tracking pharmaceutical equities and those with specific interest in women's health products. TherapeuticsMD is known for its involvement in commercializing several prescription prenatal vitamin products marketed under the BocaGreenMD and vitaMedMD brands.

Cantor Fitzgerald also weighed in, maintaining a "neutral" rating for TXMD on their latest report. These assessments provide a broad view on the company's stock for potential investors and market watchers.

Detailed Stock Performance

TXMD stock debuted the day at $2.00, under observation. The current 50-day moving average stands at $2.77, trailing behind the 200-day moving average which records $3.57. A year's activity saw the shares touching a low of $1.95 and a high of $7.18, delineating the volatility and the window of investment opportunity the stock currently possesses.

Quarterly Earnings Report

On the earnings front, TherapeuticsMD posted its quarterly report on August 14th, disclosing a ($0.24) earnings per share (EPS), which fell short of the projected ($0.07) by a significant margin of ($0.17). The company's revenue for the quarter stood at $0.44 million. A glimpse into the financial health of the company showed a net margin of 61.23% and a return on equity reaching 232.35%. Analyst consensus estimates the company to achieve an EPS of -$0.75 for the current fiscal year.

Institutional Investor Activity

Several large investors have demonstrated their confidence in TXMD by adjusting their stake in the company. Principal Financial Group Inc. PFG, headquartered in Des Moines, Iowa, upped its share by 6.3%, amounting to 123,319 shares valued around $47,000. New York-based JPMorgan Chase & Co. JPM augmented its portfolio by 22.6%, owning 255,249 shares worth approximately $97,000. Boston's State Street Corp STT increased its position by 13.6%, holding 30,130 shares valued at $113,000.

Rhumbline Advisers and UBS Group AG UBS, based in Zurich, Switzerland, also made significant share acquisitions, with the latter's holdings spiking by a substantial 258.1% in the second quarter. Overall, institutional investors and hedge funds own 28.68% of TXMD's outstanding shares.

About TherapeuticsMD

TXMD, with its head office in Boca Raton, Florida, dedicates itself to pharmaceutical innovations in the field of women's health. Besides prescription pharmaceuticals, it also offers prenatal vitamins, engaging with wholesale distributors and retail pharmacy distributors for product sales.

StockNews, TherapeuticsMD, Coverage